Quark Venture, GF Securities invest $33 mln in Microbion
Microbion Corp, a Vancouver and Bozeman, Montana biopharmaceutical company, has secured about $33 million (US$25 million) in funding. The investment was made by a health sciences fund recently launched by Canadian venture capital firm Quark Venture and China's GF Securities Co Ltd. Microbion specializes in the treatment of hard-to-treat and antibiotic-resistant infections. It plans to use the funds raised to advance a new class of drug products that address infections by attacking both bacteria and related microbial biofilms. Founded in 2000, the company is led by Chairman and CEO Karim Lalji.
6 January 2017•4 mins read
